Subependymal giant cell astrocytoma secondary prevention
|
Subependymal giant cell astrocytoma Microchapters |
|
Differentiating Subependymal Giant Cell Astrocytoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Subependymal giant cell astrocytoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Subependymal giant cell astrocytoma secondary prevention |
|
FDA on Subependymal giant cell astrocytoma secondary prevention |
|
CDC on Subependymal giant cell astrocytoma secondary prevention |
|
Subependymal giant cell astrocytoma secondary prevention in the news |
|
Blogs on Subependymal giant cell astrocytoma secondary prevention |
|
Risk calculators and risk factors for Subependymal giant cell astrocytoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Secondary Prevention
Effective measures for the secondary prevention of subependymal giant cell astrocytoma include:
- Brain imaging, preferably magnetic resonance imaging with and without contrast, should be performed every 1 to 3 years until the age of 25 years in every patient with tuberous sclerosis.
- Follow-up magnetic resonance imaging may not be needed every 3 years, but intervals may be prolonged in the presence of a stable lesion and a stable patient.
- Screening and follow-up scans frequency should be tailored according to various clinical factors.
- New onset of symptoms such as headache, visual complaints, nausea, vomiting, or increase in seizure activity should trigger an earlier MRI scan.
- Similarly, a growing subependymal giant cell astrocytoma should prompt a more frequent clinical and radiological follow-up.